We are primarily focused on developing molecular targeted therapeutics.

We are breaking down the ground of traditional drug design schemes, aiming at the defect of existing drug design methods in the pharmaceutical industry, in an aim to design better small molecule medicines using the new generation of chemical synthesis methods and molecular technologies emerging from the practice of modern synthesis and pharmaceutical industry, while creating in-depth master-key-compounds of intellectual property rich in highly commercial potential. Our long term goal is to transform the drug design and creative disruptive model in research and discovery.

Our discovery of new drug candidates is enabled by advanced chemical synthesis and medicinal chemistry methods that gives us broad chemical access to frontier oncological targets. We draw on a diverse set of chemical fragments and modular templates to identify and elaborate initial drug-like leads that are further optimized to modulate the target of interest with superior potency and specificity.